We plan to have a panel discussion on contemporary challenges/best practices in the tech transfer and CRO space, such as: How has the challenging funding cycle in 2023 affected your outsourcing processes? What is one surprising thing that you or your organization (or both) have realized? How has the funding crunch impacted your decision(s) for growth internally/externally, particularity as it relates to build/buy decisions? What are some ways your organization is using novel business models, challenges and solutions to optimize technology transfer and outsourcing (e.g., remote work)? How do you obtain new technologies/molecules externally to accelerate the drug development process? How has that changed? How can outsourcing help use R&D resources more efficiently (or does it)? What kinds of research is particularly challenging for technology transfer or outsourcing? What do you keep ‘in-house’ no matter what?
.png)